EGFR and non-small cell lung carcinoma: Since the first-generation EGFR-TKIs such as gefitinib and erlotinib were approved for the treatment of NSCLC in the early 2000s 25,26, TKIs have achieved some clinical benefits in the treatment of NSCLC with common EGFR activating mutations such as L858R and del E746-A750 27,28.